Avoiding Drug Review Limbo
This article was originally published in RPM Report
Executive Summary
Given the increased number of missed user fee deadlines in the past few years, industry executives have some advice for FDA on how to could make those misses less painful for drug sponsors: communicate a revised goal date.
You may also be interested in...
The State of New Drug Reviews in the US
Drug approvals are up. FDA is back to on-time reviews for most new drug applications. The user fee era survived its toughest test. But industry still needs to adjust to a changed environment forthe new realities of new drug reviews in the US.
FDA's Next-Generation Review Process: Avoiding the "Crisis Mentality"
There are changes coming to FDA's drug review process that, over the long term, should make the system more predictable and increase the chances for a first-cycle approval. Until then, expect a less forgiving agency when it comes to incomplete submissions-and challenges that may threaten the sanctity of priority reviews.
FDA and Health Care Reform: An Activist Agenda for the Agency
Everyone is gearing up for a debate over health care reform in 2009-including the Food & Drug Administration. The regulator's role may be bigger than you think.